Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2015 (2015), Article ID 280238, 9 pages
http://dx.doi.org/10.1155/2015/280238
Research Article

Adsorption of Toll-Like Receptor 4 Agonist to Alum-Based Tetanus Toxoid Vaccine Dampens Pro-T Helper 2 Activities and Enhances Antibody Responses

Department of Immunology, Institute of Biomedical Science, University of São Paulo, 05508-000 São Paulo, SP, Brazil

Received 24 October 2014; Accepted 4 January 2015

Academic Editor: Diana Boraschi

Copyright © 2015 Juliana Bortolatto et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. P. Gomariz, I. Gutiérrez-Cañas, A. Arranz et al., “Peptides targeting toll-like receptor signalling pathways for novel immune therapeutics,” Current Pharmaceutical Design, vol. 16, no. 9, pp. 1063–1080, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. N. W. Palm and R. Medzhitov, “Immunostimulatory activity of haptenated proteins,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 12, pp. 4782–4787, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Maisonneuve, S. Bertholet, D. J. Philpott, and E. de Gregorio, “Unleashing the potential of NOD- and toll-like agonists as vaccine adjuvants,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 34, pp. 12294–12299, 2014. View at Publisher · View at Google Scholar
  4. A. U. Bielinska, P. E. Makidon, K. W. Janczak et al., “Distinct pathways of humoral and cellular immunity induced with the mucosal administration of a nanoemulsion adjuvant,” The Journal of Immunology, vol. 192, no. 6, pp. 2722–2733, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Kawai and S. Akira, “The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors,” Nature Immunology, vol. 11, no. 5, pp. 373–384, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Miyake and T. Kaisho, “Homeostatic inflammation in innate immunity,” Current Opinion in Immunology, vol. 30, pp. 85–90, 2014. View at Publisher · View at Google Scholar
  7. F. Steinhagen, T. Kinjo, C. Bode, and D. M. Klinman, “TLR-based immune adjuvants,” Vaccine, vol. 29, no. 17, pp. 3341–3355, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Schnare, G. M. Barton, A. C. Holt, K. Takeda, S. Akira, and R. Medzhitov, “Toll-like receptors control activation of adaptive immune responses,” Nature Immunology, vol. 2, no. 10, pp. 947–950, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. D. H. Song and J.-O. Lee, “Sensing of microbial molecular patterns by Toll-like receptors,” Immunological Reviews, vol. 250, no. 1, pp. 216–229, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Booth, H. Wilson, S. Jimbo, and G. Mutwiri, “Modulation of B cell responses by Toll-like receptors,” Cell and Tissue Research, vol. 343, no. 1, pp. 131–140, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Pelka and E. Latz, “Getting closer to the dirty little secret,” Immunity, vol. 34, no. 4, pp. 455–458, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. J. M. Brewer, “(How) do aluminium adjuvants work?” Immunology Letters, vol. 102, no. 1, pp. 10–15, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Pasare and R. Medzhitov, “Control of B-cell responses by Toll-like receptors,” Nature, vol. 438, no. 7066, pp. 364–368, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. A. L. Gavin, K. Hoebe, B. Duong et al., “Adjutant-enhanced antibody responses in the absence of toll-like receptor signaling,” Science, vol. 314, no. 5807, pp. 1936–1938, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Rodríguez, A. C. Keller, E. L. Faquim-Mauro et al., “Bacterial lipopolysaccharide signaling through Toll-like receptor 4 suppresses asthma-like responses via nitric oxide synthase 2 activity,” The Journal of Immunology, vol. 171, no. 2, pp. 1001–1008, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. D. de Sousa Mucida, A. de Castro Keller, E. C. Fernvik, and M. Russo, “Unconventional strategies for the suppression of allergic asthma,” Current Drug Targets—Inflammation and Allergy, vol. 2, no. 2, pp. 187–195, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. A. K. Leung, “Anaphylaxis to DPT vaccine,” Journal of the Royal Society of Medicine, vol. 78, article 175, 1985. View at Google Scholar
  18. J. Bortolatto, É. Borducchi, D. Rodriguez et al., “Toll-like receptor 4 agonists adsorbed to aluminium hydroxide adjuvant attenuate ovalbumin-specific allergic airway disease: role of MyD88 adaptor molecule and interleukin-12/interferon-γ axis,” Clinical & Experimental Allergy, vol. 38, no. 10, pp. 1668–1679, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. S. C. Eisenbarth, “Use and limitations of alum-based models of allergy,” Clinical and Experimental Allergy, vol. 38, no. 10, pp. 1572–1575, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. A. M. Didierlaurent, S. Morel, L. Lockman et al., “AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity,” The Journal of Immunology, vol. 183, no. 10, pp. 6186–6197, 2009. View at Publisher · View at Google Scholar
  21. V. Mata-Haro, C. Cekic, M. Martin, P. M. Chilton, C. R. Casella, and T. C. Mitchell, “The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4,” Science, vol. 316, no. 5831, pp. 1628–1632, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Russo, M.-A. Nahori, J. Lefort et al., “Suppression of asthma-like responses in different mouse strains by oral tolerance,” The American Journal of Respiratory Cell and Molecular Biology, vol. 24, no. 5, pp. 518–526, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. M. D. Decker and K. M. Edwards, “Issues in design of clinical trials of combination vaccines,” Annals of the New York Academy of Sciences, vol. 754, pp. 234–240, 1995. View at Publisher · View at Google Scholar · View at Scopus
  24. R. A. Insel, “Potential alterations in immunogenicity by combining or simultaneously administering vaccine components,” Annals of the New York Academy of Sciences, vol. 754, pp. 35–47, 1995. View at Publisher · View at Google Scholar · View at Scopus
  25. J. W. Almond, “Vaccine renaissance,” Nature Reviews Microbiology, vol. 5, no. 7, pp. 478–481, 2007. View at Publisher · View at Google Scholar
  26. T. Kawai and S. Akira, “Toll-like receptors and their crosstalk with other innate receptors in infection and immunity,” Immunity, vol. 34, no. 5, pp. 637–650, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Volpi, F. Fallarino, M. T. Pallotta et al., “High doses of CpG oligodeoxynucleotides stimulate a tolerogenic TLR9-TRIF pathway,” Nature Communications, vol. 4, article 1852, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. H. Nakajima, A. Nakao, Y. Watanabe, S. Yoshida, and I. Iwamoto, “IFN-α inhibits antigen-induced eosinophil and CD4+ T cell recruitment into tissue,” Journal of Immunology, vol. 153, no. 3, pp. 1264–1270, 1994. View at Google Scholar · View at Scopus
  29. J. D. Hunt, D. C. Jackson, L. E. Brown, P. R. Wood, and D. J. Stewart, “Antigenic competition in a multivalent foot rot vaccine,” Vaccine, vol. 12, no. 5, pp. 457–464, 1994. View at Publisher · View at Google Scholar · View at Scopus
  30. S. A. Halperin, J. M. Langley, and B. J. Eastwood, “Effect of inactivated poliovirus vaccine on the antibody response to Bordetella pertussis antigens when combined with diphtheria-pertussis-tetanus vaccine,” Clinical Infectious Diseases, vol. 22, no. 1, pp. 59–62, 1996. View at Publisher · View at Google Scholar · View at Scopus
  31. S. K. Jatana and M. N. G. Nair, “Combination vaccines,” Medical Journal Armed Forces India, vol. 63, no. 2, pp. 167–171, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. A. S. Postema, M. G. Myers, and R. F. Breiman, “Challenges in the development, licensure, and use of combination vaccines,” Clinical Infectious Diseases, vol. 33, supplement 4, pp. S261–S266, 2001. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Sun, M. Walsh, A. V. Villarino et al., “TLR ligands can activate dendritic cells to provide a MyD88-dependent negative signal for Th2 cell development,” The Journal of Immunology, vol. 174, no. 2, pp. 742–751, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. J. M. Blander and R. Medzhitov, “Toll-dependent selection of microbial antigens for presentation by dendritic cells,” Nature, vol. 440, no. 7085, pp. 808–812, 2006. View at Google Scholar
  35. P. S. Creticos, J. T. Schroeder, R. G. Hamilton et al., “Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis,” The New England Journal of Medicine, vol. 355, no. 14, pp. 1445–1455, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. K.-M. Beeh, F. Kanniess, F. Wagner et al., “The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma,” Journal of Allergy and Clinical Immunology, vol. 131, no. 3, pp. 866–874, 2013. View at Publisher · View at Google Scholar · View at Scopus